Search results
Results from the WOW.Com Content Network
GINA conducts continuous review of scientific publications on asthma and is a leader in disseminating information about the care of patients with asthma. [2] GINA publishes resources such as evidence-based guidelines for asthma management, and runs special events such as World Asthma Day. GINA's guidelines, revised each year, are used by ...
Systematic review and individual patient data meta analysis research [15] in the centre has shown that, even with little training, people on oral anticoagulation can successfully self-monitor, and even self-manage their disease in the community. [16] Patients capable of self-monitoring and self-adjusting therapy have fewer thromboembolic events ...
The PRISMA flow diagram, depicting the flow of information through the different phases of a systematic review. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is an evidence-based minimum set of items aimed at helping scientific authors to report a wide array of systematic reviews and meta-analyses, primarily used to assess the benefits and harms of a health care ...
The Centers for Disease Control and Prevention estimate that 1 in 11 children and 1 in 12 adults have asthma in the United States of America. [1] According to the World Health Organization, asthma affects 235 million people worldwide. [2] There are two major categories of asthma: allergic and non-allergic.
Irritant-induced (occupational) asthma is a non-immunologic form of asthma that results from a single or multiple high dose exposure to irritant products. It is usually develops early after exposure; however, it can also develop insidiously over a few months after a massive exposure to a complex mixture of alkaline dust and combustion products ...
Asthma phenotyping and endotyping has emerged as a novel approach to asthma classification inspired by precision medicine which separates the clinical presentations of asthma, or asthma phenotypes, from their underlying causes, or asthma endotypes. The best-supported endotypic distinction is the type 2-high/type 2-low distinction.
AERD affects an estimated 0.3–0.9% of the general population in the US, including around 7% of all asthmatics, about 14% of adults with severe asthma, and ~5-10% of patients with adult onset asthma. [2] [3] [8] AERD is uncommon among children, with around 6% of patients, predominantly female, reporting disease onset during childhood. [9]
LABAs are designed to reduce the need for shorter-acting β 2 agonists such as salbutamol (albuterol), as they have an approximately twelve-hour duration of action, compared to about five hours for salbutamol, making them candidates for sparing high doses of corticosteroids [citation needed] or treating nocturnal asthma and providing ...